Edition:
United Kingdom

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

14.20USD
23 Feb 2018
Change (% chg)

$0.13 (+0.92%)
Prev Close
$14.07
Open
$14.11
Day's High
$14.52
Day's Low
$13.91
Volume
32,164
Avg. Vol
89,213
52-wk High
$26.74
52-wk Low
$11.81

Chart for

About

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121... (more)

Overall

Beta: --
Market Cap(Mil.): $547.77
Shares Outstanding(Mil.): 24.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals

* ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10 Source text: (http://bit.ly/2DaEc0a) Further company coverage:

12 Jan 2018

Future of Kala Pharma's dry eye drug uncertain after mixed results

Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.

05 Jan 2018

UPDATE 2-Future of Kala Pharma's dry eye drug uncertain after mixed results

* Peak sales could hit $1.9 bln in 2027 - analyst (Recasts lede, updates shares, adds analyst comments)

05 Jan 2018

REFILE-Kala Pharma posts mixed results from dry eye disease drug studies

Jan 5 Kala Pharmaceuticals Inc on Friday reported mixed results from two late-stage trials testing its drug to provide temporary relief from the signs and symptoms of dry eye disease.

05 Jan 2018

BRIEF-Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA

* KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION

05 Jan 2018

BRIEF-Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121

* KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE

05 Jan 2018

BRIEF-Kala Pharmaceuticals reports Q3 loss per share $0.56

* Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update

07 Nov 2017

BRIEF-Kala Pharmaceuticals submits new drug application for Inveltystm

* Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct) Source text for Eikon: Further company coverage:

25 Oct 2017

Earnings vs. Estimates